January 2024: Approved for the major project of Shenzhen Science and Technology Innovation Commission, "Key Technology Research and Development of Gene Therapy Drugs for Treating Rare Genetic Diseases".
May 2024: Approved for the ISO9001-2015 certificate, continuously maintaining the normal operation of the GMP system.

October 2024: Complete the enrollment and cell preparation of all 8 patients in the Phase 1 registration clinical trial;

November 2024: Received the SFDA delegation from Saudi Arabia and the CEO of SFDA, and completed the submission of clinical application materials for Saudi Arabia.

November 2024: Conduct research on the expansion and rejuvenation of hematopoietic stem cells, and reach a scientific research cooperation with the Blood Disease Hospital and the Institute of Blood Diseases, Chinese Academy of Medical Sciences.

December 2024：it was recognized as a National High-tech Enterprise of China and a Specialized, Refined, distinctive and Innovative Enterprise in Shenzhen.

January 2023：The research results on the mechanism of single-cell blood stem cells were accepted for publication in Clinical and Translational Medicine:

February 2023: The first patient treated with HGI-001 injection has been free from blood transfusion for two years.
February 2023: The kick-off meeting for the clinical trial of HGI-002 injection (for alpha-thalassemia) was successfully held.

January 2022: Completed the first round of 20 million financing

February 2022: First patient achieved blood transfusion independence for one year

February 2021: Completed engineered cell reinfusion of the first patient

July 2021: HGI was officially registered and established

July 2021: Assisted the partner hospital to complete the first case of "CD34+-SCB" in Shenzhen for the treatment of graft dysfunction

September 2021: HGI won second prize in the Yantian sub-venue of the "Science and Technology China" Innovation and Venture Capital Conference (2021)

July 2020: Completed the construction of GMP standard facility

September 2020: Completed gene therapy preparation for the first patient

November 2020: Pre-clinical study results accepted for publication in Human Gene Therapy

June 2019: Established the genetic engineering platform 

November 2019: Completed the preparation of lentiviral vector